Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:DGX NASDAQ:EXAS NYSE:LH NASDAQ:MYGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDGXQuest Diagnostics$188.23-1.4%$198.21$164.65▼$213.50$20.84B0.6984,539 shs123,377 shsEXASExact Sciences$104.91$103.67$38.81▼$104.98$20.03B1.413.55 million shsN/ALHLabcorp$253.82-1.6%$269.03$239.67▼$293.72$20.79B0.91693,647 shs111,686 shsMYGNMyriad Genetics$4.29+4.8%$4.77$3.75▼$8.59$404.68M1.811.58 million shs463,801 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDGXQuest Diagnostics+0.95%-1.91%-3.01%+0.01%+8.09%EXASExact Sciences0.00%0.00%0.00%+1.68%+97.02%LHLabcorp+0.13%+0.27%-4.31%-7.20%+4.66%MYGNMyriad Genetics-0.49%-13.89%-13.71%-20.12%-4.01%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDGXQuest Diagnostics$188.23-1.4%$198.21$164.65▼$213.50$20.84B0.6984,539 shs123,377 shsEXASExact Sciences$104.91$103.67$38.81▼$104.98$20.03B1.413.55 million shsN/ALHLabcorp$253.82-1.6%$269.03$239.67▼$293.72$20.79B0.91693,647 shs111,686 shsMYGNMyriad Genetics$4.29+4.8%$4.77$3.75▼$8.59$404.68M1.811.58 million shs463,801 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDGXQuest Diagnostics+0.95%-1.91%-3.01%+0.01%+8.09%EXASExact Sciences0.00%0.00%0.00%+1.68%+97.02%LHLabcorp+0.13%+0.27%-4.31%-7.20%+4.66%MYGNMyriad Genetics-0.49%-13.89%-13.71%-20.12%-4.01%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDGXQuest Diagnostics 2.50Moderate Buy$216.5815.07% UpsideEXASExact Sciences 1.95Reduce$92.13-12.19% DownsideLHLabcorp 2.73Moderate Buy$308.0021.35% UpsideMYGNMyriad Genetics 2.00Hold$6.4049.36% UpsideCurrent Analyst Ratings BreakdownLatest EXAS, LH, MYGN, and DGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026MYGNMyriad Genetics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$7.00 ➝ $6.005/6/2026MYGNMyriad Genetics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$6.00 ➝ $5.505/4/2026DGXQuest Diagnostics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy (B) ➝ Buy (B+)5/1/2026LHLabcorp Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$334.004/22/2026DGXQuest Diagnostics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$210.00 ➝ $220.004/22/2026DGXQuest Diagnostics BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$225.00 ➝ $230.004/22/2026DGXQuest Diagnostics Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$224.00 ➝ $229.004/22/2026DGXQuest Diagnostics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$220.00 ➝ $225.004/21/2026DGXQuest Diagnostics EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$225.004/21/2026DGXQuest Diagnostics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$225.004/13/2026MYGNMyriad Genetics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDGXQuest Diagnostics$11.04B1.89$15.11 per share12.46$69.25 per share2.72EXASExact Sciences$3.25B6.17$1.27 per share82.83$12.58 per share8.34LHLabcorp$14.14B1.47$24.52 per share10.35$106.45 per share2.38MYGNMyriad Genetics$824.50M0.49$3.93 per share1.09$3.57 per share1.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDGXQuest Diagnostics$992M$9.0520.8016.322.259.07%15.60%7.06%N/AEXASExact Sciences-$207.95M-$1.10N/A209.822.02-6.40%0.53%0.22%N/ALHLabcorp$876.50M$11.2922.4613.101.806.66%16.29%7.62%7/23/2026 (Estimated)MYGNMyriad Genetics-$365.90M-$4.30N/AN/AN/A-48.24%-8.51%-4.48%N/ALatest EXAS, LH, MYGN, and DGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2026Q1 2026MYGNMyriad Genetics-$0.06-$0.09-$0.03-$0.36$202.42 million$200.40 million4/30/2026Q1 2026LHLabcorp$4.09$4.25+$0.16$3.35$3.51 billion$3.54 billion4/21/2026Q1 2026DGXQuest Diagnostics$2.37$2.50+$0.13$2.24$2.83 billion$2.90 billion2/23/2026Q4 2025MYGNMyriad Genetics-$0.02$0.04+$0.06-$0.08$207.57 million$209.80 million2/17/2026Q4 2025LHLabcorp$3.95$4.07+$0.12$1.98$3.56 billion$3.52 billion2/13/2026Q4 2025EXASExact Sciences$0.08-$0.21-$0.29-$0.45$860.59 million$878.38 million2/10/2026Q4 2025DGXQuest Diagnostics$2.35$2.42+$0.07$2.18$2.75 billion$2.81 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDGXQuest Diagnostics$3.441.83%+7.34%38.01%14 YearsEXASExact SciencesN/AN/AN/AN/AN/ALHLabcorp$2.881.13%N/A25.51%N/AMYGNMyriad GeneticsN/AN/AN/AN/AN/ALatest EXAS, LH, MYGN, and DGX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/9/2026LHLabcorpquarterly$0.721.05%5/29/20265/29/20266/11/20262/10/2026DGXQuest Diagnosticsquarterly$0.861.73%4/6/20264/6/20264/20/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDGXQuest Diagnostics0.671.181.08EXASExact Sciences0.972.432.17LHLabcorp0.681.731.54MYGNMyriad Genetics0.362.402.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDGXQuest Diagnostics88.06%EXASExact Sciences88.82%LHLabcorp95.94%MYGNMyriad Genetics99.02%Insider OwnershipCompanyInsider OwnershipDGXQuest Diagnostics0.88%EXASExact Sciences1.20%LHLabcorp0.84%MYGNMyriad Genetics1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDGXQuest Diagnostics57,000110.70 million109.72 millionOptionableEXASExact Sciences7,200190.89 million188.60 millionOptionableLHLabcorp71,00082.00 million81.31 millionOptionableMYGNMyriad Genetics2,70094.44 million92.65 millionOptionableEXAS, LH, MYGN, and DGX HeadlinesRecent News About These CompaniesPiper Sandler Reaffirms Their Buy Rating on Myriad Genetics (MYGN)May 7 at 7:19 PM | theglobeandmail.comMyriad Genetics to Participate in Upcoming Investor Healthcare ConferencesMay 7 at 4:05 PM | globenewswire.comMyriad Genetics (NASDAQ:MYGN) Price Target Cut to $6.00 by Analysts at TD CowenMay 7 at 4:34 AM | americanbankingnews.comMyriad Genetics (NASDAQ:MYGN) Price Target Cut to $5.50 by Analysts at Wells Fargo & CompanyMay 7 at 4:34 AM | americanbankingnews.comTD Cowen Lowers Myriad Genetics (NASDAQ:MYGN) Price Target to $6.00May 6 at 4:06 PM | marketbeat.comMyriad Genetics in record sell-off after Q1 missMay 6 at 2:39 PM | seekingalpha.comMyriad Genetics (NASDAQ:MYGN) Given New $5.50 Price Target at Wells Fargo & CompanyMay 6 at 10:24 AM | marketbeat.comMyriad Genetics, Inc. (MYGN) Q1 2026 Earnings Call TranscriptMay 5 at 12:00 AM | seekingalpha.comMyriad Genetics Q1 Earnings Call HighlightsMay 5 at 9:34 PM | marketbeat.comMyriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue EstimatesMay 5 at 9:31 PM | zacks.comMyriad Genetics (NASDAQ:MYGN) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPSMay 5 at 7:21 PM | marketbeat.comMyriad: Q1 Earnings SnapshotMay 5 at 7:12 PM | finance.yahoo.comMyriad Genetics (NASDAQ:MYGN) misses Q1 CY2026 sales expectations, stock drops 16.2%May 5 at 7:12 PM | msn.comMyriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum BusinessMay 5 at 4:05 PM | globenewswire.comMyriad Genetics (MYGN) To Report Earnings Tomorrow: Here Is What To ExpectMay 4, 2026 | finance.yahoo.comAnalyzing Myriad Genetics (NASDAQ:MYGN) and Tectonic Therapeutic (NASDAQ:TECX)May 4, 2026 | americanbankingnews.comMyriad Genetics (MYGN) Projected to Post Earnings on TuesdayMay 3, 2026 | americanbankingnews.comMyriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care PlanApril 30, 2026 | markets.businessinsider.comMyriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026April 28, 2026 | globenewswire.comAnalysts Estimate Myriad Genetics (MYGN) to Report a Decline in Earnings: What to Look Out forApril 28, 2026 | zacks.comMyriad Genetics (MYGN) to Release Quarterly Earnings on TuesdayApril 28, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesIndustrial Chips Are in Rally Mode—5 Ways to PlayBy Thomas Hughes | April 27, 2026Texas Instruments Surges 18% as Data Center Demand Spikes 90%By Thomas Hughes | April 24, 2026Comparing 3 Cruise Stocks: Which Has the Most Upside in 2026?By Jennifer Ryan Woods | April 21, 2026Norwegian Cruise Line Cuts Outlook as Headwinds BuildBy Jennifer Ryan Woods | May 5, 2026AI Is Reviving an Overlooked Chip Category—and These 3 Names Are Riding the Demand WaveBy Nathan Reiff | April 29, 2026EXAS, LH, MYGN, and DGX Company DescriptionsQuest Diagnostics NYSE:DGX$188.22 -2.62 (-1.37%) As of 11:32 AM Eastern This is a fair market value price provided by Massive. Learn more.Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.Exact Sciences NASDAQ:EXASExact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.Labcorp NYSE:LH$253.82 -4.24 (-1.64%) As of 11:32 AM Eastern This is a fair market value price provided by Massive. Learn more.Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.Myriad Genetics NASDAQ:MYGN$4.28 +0.20 (+4.77%) As of 11:32 AM Eastern This is a fair market value price provided by Massive. Learn more.Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
